Current stock page

Financial Data

ZYME Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

ZYMEZymeworks Inc.

Healthcare / Biotechnology

Leader

Strong Relative Position

BullishEdge 8/10
$26.24−$0.23 (−0.87%)

Latest quote

  • Momentum
    78
  • Value
    66
  • Quality
    62
  • Risk resilience
    61
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$256.46M$4.59M$2.41M$2.52M$27.61M$48.73M$27.11M$31.03M
Gross Profit$256.46M$4.59M-$439K$824K$27.61M$48.73M$27.11M$31.03M
Operating Income$177.6M-$42.18M-$47.12M-$44.15M-$22.11M-$674K-$25.61M-$22.22M
Net Income$173.7M-$45.02M-$44.16M-$41.21M-$19.6M$2.32M-$22.64M-$23.51M
EPS$2.43-$0.62-$0.59-$0.55-$0.26$0.03-$0.3-$0.31
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$24.04M-$31.95M-$45.72M-$9.98M-$31.41M$12.07M-$3.41M-$41.51M
Capital Expenditure-$73K$0-$216K-$569.9K-$410K-$884K-$338K-$314K
Free Cash Flow-$24.11M-$31.95M-$45.72M-$10.55M-$31.82M$11.19M-$3.75M-$41.82M
Net Cash Provided By Operating Activities-$24.04M-$31.95M-$45.72M-$9.98M-$31.41M$12.07M-$3.41M-$41.51M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$1.18B$396.96M$478.22M$346.53M$397.27M$408.39M$425.52M$463.09M
Total Debt$650.28M$268.64M$17.04M$18.27M$18.9M$18.68M$18.46M$18.51M
Cash And Cash Equivalents$100.46M$179.41M$244.28M$41.16M$64.83M$98.25M$76.2M$66.1M
Total Liabilities$918.16M$316.6M$314.63M$78.03M$77.21M$73.88M$100.56M$124.32M
Total Stockholders Equity$258.25M$80.37M$163.59M$268.5M$320.06M$334.51M$324.97M$338.77M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio54.24———————
P/B ratio9.121.0112.156.544.242.812.622.95
P/S ratio7.06———————
Debt To Equity2.523.340.10.070.060.060.060.05
Free Cash Flow Yield-4.78%-7.11%-3.87%-1.99%-4.88%-4.38%-9.22%-11.31%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio54.24———————
P/B ratio9.121.0112.156.544.242.812.622.95
P/S ratio7.06———————
Return On Equity16.77%-186.63%-62.75%-30.22%-19.82%-22.03%-34.98%-36.22%
Debt To Equity2.523.340.10.070.060.060.060.05

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe39.16x
Pb7.28x
Revenue Growth Yoy828.73%
EPS Growth Yoy1034.62%
Gross Margin98.29%
Operating Margin16.60%
ROE22.48%
ROIC4.30%
Debt To Equity2.52
FCF Yield-6.15%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$26.24
Volume774,983
RSI (14)41.96
MACD0.38
MACD signal0.71
MACD histogram-0.33
ADX (14)23.8
SMA (50)$27.32
SMA (200)$25.52
ATR (14)$1.43
Historical volatility (annualized)63.12%
Volume (20-day average)1.38M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score61/100
Beta0.78
Annual volatility54.03%
Max Drawdown-23.63%
Sharpe Ratio0.84
VaR (95%, 1-day)-4.13%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

ZYME Financial Data FAQ

What is Zymeworks Inc.'s revenue?

Zymeworks Inc.'s revenue is one of the core financial data points for ZYME. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Zymeworks Inc.'s revenue growing?

Revenue growth shows whether Zymeworks Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is ZYME's EPS?

ZYME's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Zymeworks Inc.'s net income?

Zymeworks Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Zymeworks Inc. generate?

Free cash flow shows how much cash Zymeworks Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Zymeworks Inc. have?

Cash and debt help frame ZYME's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.